Trial Profile

An Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a patient with ApoCII amyloidosis

Status: Planning

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 Jul 2025 New trial record
08 Jul 2025 According to ZyVersa Therapeutics media release, this emergency compassionate use program will follow the protocol of ongoing DKD clinical trial, VAR200-0301.
08 Jul 2025 According to ZyVersa Therapeutics media release, patient with ApoCII amyloidosis will receive treatment at the University of Miami Peggy and Harold Katz Family Drug Discovery Center under the care of the Center Director, Dr. Alessia Fornoni and VAR 200 inventor.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com